Defiance Leveraged Long +Income HIMS ETF

Hims & Hers Health Increases Convertible Note Offering to $350 Million

Hims & Hers Health Average Target Price Rises to $27.51

JPMorgan Downgrades Hims & Hers Health's Price Target to $33

Hims & Hers Health Misses Q1 Earnings Estimates, Shares Fall

Oppenheimer & Co. Significantly Reduces Holdings in Hims & Hers Health

Hims & Hers Health's Chief Legal Officer Sold Company Stocks

Hims & Hers Reports FY2025 Revenue and FY2026 Forecast

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

HIMS

HIMZ

HIMY

Hims & Hers Health CFO Oluyemi Okupe sold 7,950 shares at $23.64 each, totaling $187,938, reducing his holdings by 2.93%. Post-sale, he owns 262,954 shares valued at approximately $6.22 million. This transaction was part of a pre-arranged trading plan and disclosed to the SEC. The company's stock has seen fluctuations, with recent earnings missing estimates and a market cap of $5.12 billion.

Market Beat

Hims & Hers Health

VG Health

SPDR S&P Health

iShares US Healthcare Providers

Defiance Daily Target 2X Long HIMS ETF

Health Care Select Sector SPDR

iShares Global Healthcare

Eli Lilly

Novo Nordisk AS

Bank of America

UBS Group AG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 7,950 Shares of Stock

Bank of America has lowered its price target for Hims & Hers Health (NYSE:HIMS) from $30.00 to $28.00, maintaining a 'neutral' rating. This suggests a potential upside of 25.44% from the current price. Other analysts have also adjusted their ratings, with Morgan Stanley setting a target of $21.00 and Citigroup raising it to $28.00. Hims & Hers Health's stock is currently trading at $22.32.

Morgan Stanley

Citigroup

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Bank of America Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $28.00

Hims & Hers is raising $350 million through a convertible debt offering, which may limit shareholder dilution but also increases business risk. The company must demonstrate growth potential to the market, as the debt could either convert to stock or require cash repayment. This move aims to fund long-term growth plans.

nasdaq

NVIDIA

Intel

S&P 500

Nasdaq

NVIDIA Corporation

Hims & Hers Massive Stock Drop Explained

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment | HIMS Stock News

StockTitan

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment | HIMS Stock News

This week, Wall Street saw declines, particularly in technology stocks, while the S&P 500 Health Care Index gained 1.09%. Notable healthcare news includes UnitedHealth's new pharmacy pricing model set for 2027, a $15.2B licensing deal between Bristol Myers Squibb and Hengrui Pharma, and Hims & Hers Health reporting disappointing Q1 results. Additionally, concerns were raised about the potential impact of Trump's drug policy on US biopharma innovation.

businessinsider

Bristol Myers Squibb

Direxion Pharma & Medical Bull 3X

Invesco S&P 500 Equal Weight Health Care ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares US Medical Devices

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

ProShares Ultra Health Care ETF

SPDR S&P Health Equip

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

Hims & Hers Health (NYSE:HIMS) has delivered an average annual return of 20.04% over the past 5 years, outperforming the market by 7.64%. An investment of $1000 in HIMS stock five years ago would now be worth $2,719.87, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $5.74 billion.

benzinga_article

$1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth This Much Today

The stock continues to be very volatile.

Is Hims and Hers Health stock a buy after its latest dip?

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Barchart Option

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

ARMK

EATZ

Top Wall Street analysts have updated their ratings on several companies. Baird raised Aramark's price target from $50 to $58, maintaining an Outperform rating, while Aramark shares closed at $48.41. Other notable changes include BMO Capital increasing Nextpower's target from $113 to $125, and Mizuho cutting Agree Realty's target from $86 to $80. Analysts also adjusted targets for companies like Arvinas, Intellia Therapeutics, and Hims & Hers Health. For a complete list of changes, see the analyst ratings page.

Aramark

AdvisorShares Restaurant ETF

Nextpower

Agree Realty

Arvinas

Intellia Therap

Sensata Tech

ZoomInfo Tech

Aecom

Arteris

AGREE REALTY CORP DEP SHS EA REP 1/1000 CUM PFD STK SR A

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Novo Nordisk partners with Hims & Hers to sell FDA-approved GLP-1 drugs to eligible customers, including Wegovy (injectable and oral) and Ozempic pens; expands retail access to these meds.1Novo Nordisk: once‑weekly semaglutide 2.4 mg cut MACE in SELECT perimenopausal women ~42% vs placebo and ~13% in postmenopausal women; subgroup difference not statistically significant.2

TradingView

Defiance Daily Target 2X Long NVO ETF

iShares US Pharma

Key facts: Novo Nordisk sells GLP‑1s via Hims & Hers;MACE down 42%/13%

Defiance Leveraged Long +Income HIMS ETF(HIMY.US)

Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 7,950 Shares of Stock

Bank of America Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $28.00

Hims & Hers Massive Stock Drop Explained

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment | HIMS Stock News

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

$1000 Invested In Hims & Hers Health 5 Years Ago Would Be Worth This Much Today

Is Hims and Hers Health stock a buy after its latest dip?

Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Key facts: Novo Nordisk sells GLP‑1s via Hims & Hers;MACE down 42%/13%